Used in cancer immunotherapy to target the CSF1 receptor on tumor-associated macrophages, thereby inhibiting their immunosuppressive activity in the tumor microenvironment. This helps enhance the anti-tumor immune response, particularly in combination with other immunotherapies like checkpoint inhibitors. Investigated in clinical trials for solid tumors including pancreatic cancer and other advanced malignancies where macrophage infiltration supports tumor progression. Also explored for use in certain inflammatory and autoimmune conditions involving abnormal macrophage activation.